slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 75,601-75,630
Pages 3,679
Rows per page 30
Component
75,601-75,630 of 110,355
06
The slide uses a four-column layout to structure the disease overview.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations 1 hit
07
The slide uses a map to show regional prevalence and a nested circle diagram to show the funnel from total infected to treated patients.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
12
Data presented at EASL 2022. Shows dual-axis line charts for viral load/ALT and bar charts for T-cell frequency.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
21
The slide uses a three-column layout to explain the scientific basis and product advantages.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
22
Includes both in vitro (IFN-y fold increase) and in vivo (MC38 tumor model) efficacy data.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
24
Includes a footnote regarding the 3/21/2023 Court Scheduling Order.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
25
The slide includes a financial disclaimer regarding cash balance and burn.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
07
The slide uses an infinity-loop style diagram to connect three pillars of leadership.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
08
The slide highlights clinical outcomes (QoL, MG-ADL scores), treatment protocols (steroid tapering), patient support (My VYVGART Path), and economic value (cost/benefit vs IVIg).argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
09
The slide uses a 2x2 grid layout to present key performance indicators.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
10
The slide uses a stacked bar/arrow hybrid to illustrate growth. The data points are 6,000 (US patients), 17,000 (RoW TAM), and 31,000 (US TAM).argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
12
Uses a visual metaphor of a patient partially submerged to represent 'unseen suffering'.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
14
Uses a pyramid-like growth visualization to represent expanding market opportunities.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
19
The slide uses a central quote to humanize the clinical problem and market opportunity.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · The BreakthroughLoop · Quick Win Big Bet1 hit
21
The slide uses two distinct scientific data visualizations: a longitudinal weight study in mice and a bar chart showing muscle contraction fidelity in an NMJ-on-a-chip model.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
25
The slide uses a bar chart to show growth and two tables for financial summaries.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
04
The slide uses a horizontal layout to segment the business into five pillars, each with specific growth drivers and outlooks.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Early StrugglesLoop · Logic Chain1 hit
06
The slide uses a structured grid to map corporate acquisitions/partnerships to strategic goals and therapeutic areas.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Early StrugglesLoop · Logic Chain1 hit
09
Includes specific drug names and market projections for 2028.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Rising SuccessLoop · Logic Chain1 hit
11
The slide uses a three-column layout to categorize business units and their respective growth drivers.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Rising Success1 hit
12
NME stands for New Molecular Entity. FDC stands for Fixed-Dose Combination.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Rising Success1 hit
13
Includes clinical development pipeline visualization and market growth projections.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Rising Success1 hit
14
Includes a table comparing hospitalization rates for RSV, hMPV, and Influenza across age groups.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Rising Success1 hit
17
The slide uses a split layout: left side details specific drug assets (anselamimab, ALXN2220) with clinical stage data, right side outlines the genomic medicine strategy.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · The BreakthroughLoop · Cost Of Inaction1 hit
19
The slide highlights both internal R&D focus areas and external acquisitions (Cellectis, Quell, Gracell) to support long-term growth.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
20
Includes specific targets for 2025, 2026, and 2030.AstraZeneca | Investor Conference Presentation Deck | 26 slides · AstraZeneca
Conference presentation Investor relations Beat · Ultimate Achievement1 hit
04
The slide uses a Gantt-style visualization to show drug development progress across Preclinical, Phase 1, Phase 2, and Phase 3 stages.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
05
The slide uses a table-like structure to track progress (checkmarks for completed, squares for upcoming) across 8 distinct drug programs.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
The slide uses a timeline-based process diagram to illustrate the clinical trial flow.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
The slide cites a third-party study (Palhano-Fontes et al.) as proxy evidence for DMT efficacy.ATAI | Investor Presentation Deck | 34 slides · atai Life Sciences
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit